287 related articles for article (PubMed ID: 19188571)
21. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.
O'Connor PW; Goodman A; Willmer-Hulme AJ; Libonati MA; Metz L; Murray RS; Sheremata WA; Vollmer TL; Stone LA;
Neurology; 2004 Jun; 62(11):2038-43. PubMed ID: 15184611
[TBL] [Abstract][Full Text] [Related]
22. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
Benkert TF; Dietz L; Hartmann EM; Leich E; Rosenwald A; Serfling E; Buttmann M; Berberich-Siebelt F
PLoS One; 2012; 7(12):e52208. PubMed ID: 23284936
[TBL] [Abstract][Full Text] [Related]
23. [Natalizumab in the treatment of multiple sclerosis].
Horga A; Horga de la Parte JF
Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
[TBL] [Abstract][Full Text] [Related]
24. Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
[TBL] [Abstract][Full Text] [Related]
25. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Rudick RA; Sandrock A
Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
[TBL] [Abstract][Full Text] [Related]
26. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
27. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
Ko HH; Bressler B
Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
[TBL] [Abstract][Full Text] [Related]
28. Washout period for immune-modifying drugs before natalizumab therapy.
Ilanjian H; Shane R
Am J Health Syst Pharm; 2008 Jan; 65(1):18-9. PubMed ID: 18159033
[No Abstract] [Full Text] [Related]
29. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.
Gordon FH; Lai CW; Hamilton MI; Allison MC; Srivastava ED; Fouweather MG; Donoghue S; Greenlees C; Subhani J; Amlot PL; Pounder RE
Gastroenterology; 2001 Aug; 121(2):268-74. PubMed ID: 11487536
[TBL] [Abstract][Full Text] [Related]
30. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
[TBL] [Abstract][Full Text] [Related]
31. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis.
O'Connor P
Expert Opin Biol Ther; 2007 Jan; 7(1):123-36. PubMed ID: 17150024
[TBL] [Abstract][Full Text] [Related]
32. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
33. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring.
Khoy K; Mariotte D; Defer G; Petit G; Toutirais O; Le Mauff B
Front Immunol; 2020; 11():549842. PubMed ID: 33072089
[TBL] [Abstract][Full Text] [Related]
34. Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation.
Capobianco M; Motuzova Y; Frau J; Cocco E; Mamusa E; Marrosu MG; Bertolotto A
Neurol Sci; 2012 Aug; 33(4):863-7. PubMed ID: 22116203
[TBL] [Abstract][Full Text] [Related]
35. [Effectiveness and safety of natalizumab in multiple sclerosis: data of the first five years from the TOP (Tysabri Observational Program)].
Magdolna S
Ideggyogy Sz; 2014 May; 67(5-6):211-2. PubMed ID: 25087382
[No Abstract] [Full Text] [Related]
36. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
Drugs R D; 2004; 5(2):102-7. PubMed ID: 15293871
[TBL] [Abstract][Full Text] [Related]
37. Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children.
Vitaliti G; Matin N; Tabatabaie O; Di Traglia M; Pavone P; Lubrano R; Falsaperla R
Expert Rev Neurother; 2015; 15(11):1321-41. PubMed ID: 26513633
[TBL] [Abstract][Full Text] [Related]
38. [Neuropathology of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy].
Kanda T
Brain Nerve; 2015 Jul; 67(7):891-901. PubMed ID: 26160817
[TBL] [Abstract][Full Text] [Related]
39. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
[TBL] [Abstract][Full Text] [Related]
40. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.
Bennett JL
Neurol Res; 2006 Apr; 28(3):291-8. PubMed ID: 16687056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
